Ginkgo Bioworks Holdings Inc致力于建立一个对细胞进行编程的平台。该公司的平台用于代表其客户对细胞进行编程。其细胞程序旨在实现产品的生物生产,例如治疗剂,关键食品成分和来自石油的化学品。该公司通过两个部门运营:Foundry和Biosecurity。Foundry部门包括根据与公司细胞编程平台相关的合作和许可协议提供的研发服务。其细胞编程平台包括两项资产:Foundry、生物实验室设施,通过在工作流、定制软件、机器人自动化和数据科学与分析方面的投资实现,该平台与公司的代码库、生物部件集合和用于细胞编程的生物数据数据库相结合。Biosecurity部门包括主要向公共卫生部门提供的新冠肺炎检测产品和服务。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Shyam Sankar | Independent Chairman of the Board | 2023 | 43 |
| Jason Kelly | Co-Founder, Co-COO, CEO & Director | 2026 | 44 |
| Reshma P. Shetty | Co-Founder, President, COO Director | 2008 | 44 |
| Christian O. Henry | Independent Director | 2016 | 58 |
| Harry Evans Sloan | Independent Director | 2021 | 76 |
| Norbert W. Bischofberger | Member of Biopharma Advisory Board | 2024 | 70 |
| Jeffrey Legos | Member of Biopharma Advisory Board | 2024 | - |
| John M. Maraganore | Member of Biopharma Advisory Board | 2024 | 64 |
| Paolo G. V. Martini | Member of Biopharma Advisory Board | 2024 | - |
| Mark Anthony McCamish | Member of Biopharma Advisory Board | 2024 | 73 |
| Christi L. Shaw | Member of Biopharma Advisory Board | 2024 | 58 |
| Ross Fubini | Independent Director | 2024 | 49 |
| Sriram Kosuri | Independent Director | 2024 | 45 |